Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252835 · ClinicalTrials.gov registry record · Phase 2
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02252835 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 32 participants.
The verdict
NCT02252835, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics, safety and potential for drug-drug interaction of arhalofenate when combined with febuxostat in adult population with gout.
Interventions
- DRUG Colchicine
- DRUG Febuxostat
- DRUG Arhalofenate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02252835
The ClinicalTrials.gov registry entry for NCT02252835 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Colchicine is the first listed.
NCT02252835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02252835 about?
NCT02252835 is a clinical study titled "Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout". The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics, safety and potential for drug-drug interaction of arhalofenate when combined with febuxostat in adult population with gout.
What is the current status of trial NCT02252835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-08. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02252835?
The interventions under investigation include: Colchicine (DRUG), Febuxostat (DRUG), Arhalofenate (DRUG).
Who is sponsoring clinical trial NCT02252835?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.